Skip to main content
. 2022 May 27;12:880008. doi: 10.3389/fonc.2022.880008

Figure 3.

Figure 3

Therapeutic choices before (A) and after (B) the beginning of dostarlimab expanded access program (EAP). ICI, immune checkpoint inhibitor other than dostarlimab.